Hederacoside C
Based on 1 Customer Validation
Hederacoside C (Kalopanaxsaponin B) is an ingredient that can be obtained mainly from ivy leaves. Hederacoside C mediates inflammation by inhibiting activation of MAPK/NF-κB and its downstream signaling pathway. Hederacoside C has anti-inflammatory and antibacterial activity.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.92%
- CAS 番号: 14216-03-6
- 分子式: C59H96O26
- 分子量:1221.38
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-10122
Silodosinα1A-AR Blocker -
HY-N0255
alpha-HederinApoptosis Inducer -
HY-N0253R
Hederacoside C (Standard)Anti-inflammatory agent -
HY-N0022
IsoacteosideNatural Product -
HY-N0031
PlantamajosideNF-κB Inhibitor -
HY-13510
Cutamesine dihydrochlorideσ1R Agonist -
HY-13510R
Cutamesine dihydrochloride (Standard)σ1R Agonist -
HY-N0022R
Isoacteoside (Standard)Natural Product -
HY-N0031R
Plantamajoside (Standard)NF-κB Inhibitor
生物活性
製品説明
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| ECV-304 | IC50 |
>164 μM
Compound: Hederacoside C
|
Cytotoxicity against human ECV304 cells after 72 hrs by Hoechst 33258 staining based fluorescence assay
Cytotoxicity against human ECV304 cells after 72 hrs by Hoechst 33258 staining based fluorescence assay
|
[PMID: 22503361] |
| ECV-304 | IC50 |
>164 μM
Compound: Hederacoside C
|
Membranolytic activity in human ECV304 cells assessed as leakage of intracellular lactate dehydrogenase after 2 hrs by spectrophotometry
Membranolytic activity in human ECV304 cells assessed as leakage of intracellular lactate dehydrogenase after 2 hrs by spectrophotometry
|
[PMID: 22503361] |
| ECV-304 | IC50 |
>164 μM
Compound: Hederacoside C
|
Cytotoxicity against human ECV304 cells after 72 hrs by MTT assay
Cytotoxicity against human ECV304 cells after 72 hrs by MTT assay
|
[PMID: 24084294] |
| ECV-304 | IC50 |
>164 μM
Compound: Hederacoside C
|
Membrane toxicity against human ECV304 cells after 2 hrs by LDH release assay
Membrane toxicity against human ECV304 cells after 2 hrs by LDH release assay
|
[PMID: 24084294] |
| HepG2 | IC50 |
0.8 μM
Compound: 9
|
Inhibition of TNF-alpha-induced NFkappaB activation in human HepG2 cells after 1 hr by luciferase reporter assay
Inhibition of TNF-alpha-induced NFkappaB activation in human HepG2 cells after 1 hr by luciferase reporter assay
|
[PMID: 21870831] |
| RAW264.7 | IC50 |
>50 μM
Compound: 16
|
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs by Griess reagent-based assay
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs by Griess reagent-based assay
|
[PMID: 30808589] |
| RAW264.7 | IC50 |
>50 μM
Compound: 23
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitirc oxide production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitirc oxide production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs by Griess assay
|
[PMID: 31301930] |
体外実験
Hederacoside C (0.1, 1, 10 μM, 1 h) inhibits MAPK/NF-κB and the activation of its downstream signaling pathway in human intestinal epithelial Caco-2 cells to reduce inflammatory response[1].
Hederacoside C (5, 10, 50 μg/mL, 1 h) has anti-inflammatory effects on RAW 264.7 cells stimulated by Staphylococcus aureus[2].
Hederacoside C (5, 10 μg/mL, 2 h) has a protective effect on ECM degradation induced by senescence of mouse chondrocytes[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Caco-2
-
Concentration:0.1, 1, 10 μM
-
Incubation Time:1 h
-
Result:Reduced the expression of p-p65/p65, p-JNK, p-ERK, and p-p38.
-
Cell Line:RAW 264.7
-
Concentration:5, 10, 50 μg/mL
-
Incubation Time:1 h
-
Result:Reduced the expressions of IL-1β, IL-6, TNF-α, and IL-10.
体内実験
Hederacoside C (5, 10, 50 mg/kg, intraperitoneally injected for 3 consecutive times for 8 h) can attenuate the breast lesions caused by Staphylococcus aureus[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:TNBS-induced colitis in rat[1]
-
Dosage:0.625, 1.25, 2.5 mg/kg
-
Administration:i.p. for 7 days
-
Result:Decreased the levels of inflammatory cytokines, including TNF-α, IL-6, IL-1β, CXCL-1, CXCL-2, and CXCL-5.
Reduced cell apoptosis in TNBS-induced colitis.
Reduced Bax/Bcl-2 ratio, cleaved caspase 3, and p53 protein levels in a dose-dependent manner.
化学情報
-
CAS 番号 14216-03-6
-
性状 Solid
-
分子量 1221.38
-
分子式 C59H96O26
-
Color White to off-white
-
SMILES
O[C@H]1[C@]([H])(O[C@@H]2[C@@H](O)[C@@H](O)CO[C@]2(O[C@@H]3[C@@](C)(CO)[C@@](CC[C@]4(C)[C@]5([H])CC=C6[C@@]4(C)CC[C@]7(C(O[C@@H]8O[C@H](CO[C@H]9[C@H](O)[C@@H](O)[C@H](O[C@@]%10([H])[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O%10)[C@@H](CO)O9)[C@@H](O)[C@H](O)[C@H]8O)=O)[C@@]6([H])CC(C)(C)CC7)([H])[C@]5(C)CC3)[H])O[C@@H](C)[C@H](O)[C@H]1O
-
別名
Kalopanaxsaponin B; ヘデラコシドC
-
Structure Classification
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
溶剤 & 溶解度
体外:
DMSO : 100 mg/mL (81.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
体内:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.05 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.05 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
プロトコル
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
純度とドキュメンテーション
-
データシート (283 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Zha ZX, et al. Hederacoside C ameliorates colitis via restoring impaired intestinal barrier through moderating S100A9/MAPK and neutrophil recruitment inactivation. Acta Pharmacol Sin. 2023 Jan;44(1):105-119. [Content Brief]
[2]. Akhtar M, et al. Hederacoside-C Inhibition of Staphylococcus aureus-Induced Mastitis via TLR2 & TLR4 and Their Downstream Signaling NF-κB and MAPKs Pathways In Vivo and In Vitro. Inflammation. 2020 Apr;43(2):579-594. [Content Brief]
[3]. Xu HC, et al. Hederacoside-C protects against AGEs-induced ECM degradation in mice chondrocytes. Int Immunopharmacol. 2020 Jul;84:106579. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.8187 mL | 4.0937 mL | 8.1875 mL | 20.4687 mL |
| 5 mM | 0.1637 mL | 0.8187 mL | 1.6375 mL | 4.0937 mL | |
| 10 mM | 0.0819 mL | 0.4094 mL | 0.8187 mL | 2.0469 mL | |
| 15 mM | 0.0546 mL | 0.2729 mL | 0.5458 mL | 1.3646 mL | |
| 20 mM | 0.0409 mL | 0.2047 mL | 0.4094 mL | 1.0234 mL | |
| 25 mM | 0.0327 mL | 0.1637 mL | 0.3275 mL | 0.8187 mL | |
| 30 mM | 0.0273 mL | 0.1365 mL | 0.2729 mL | 0.6823 mL | |
| 40 mM | 0.0205 mL | 0.1023 mL | 0.2047 mL | 0.5117 mL | |
| 50 mM | 0.0164 mL | 0.0819 mL | 0.1637 mL | 0.4094 mL | |
| 60 mM | 0.0136 mL | 0.0682 mL | 0.1365 mL | 0.3411 mL | |
| 80 mM | 0.0102 mL | 0.0512 mL | 0.1023 mL | 0.2559 mL |
Hederacoside C 関連分類
HY-N0253 関連分類
Powered by Bioz